CD8B and diffuse large B-cell lymphoma: In this study, HJ901 treatment significantly reduced cell proliferation not only in human PBMCs treated with IMQ or CpG 685 but also in ABC-DLBCL cells OCI-Ly3.3, OCI-Ly10, and TMD8 with the MyD88 L265P oncogenic mutation confirmed by Sanger sequencing.